Thomas Gary

TL;DR: The 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines, which are based on a systematic review of the literature published up to December, 2018, are presented along with a Grading of Recommendations Assessment Development and Evaluation scale methods.

TL;DR: The PLR is a broadly available and cheap marker, which could be used to highlight patients at high risk for vascular endpoints and its association with critical limb ischemia (CLI) and other vascular end points in peripheral arterial occlusive disease (PAOD) patients is investigated.

TL;DR: The lymphocyte‐to‐monocyte ratio (LMR) is easily determined from the white blood cell count and its association with critical limb ischemia and other vascular endpoints in PAOD patients is investigated.

TL;DR: An increased NLR is significantly associated with patients at high risk for CLI and other vascular endpoints in peripheral arterial occlusive disease patients, and could be used to highlight patients athigh risk for vascular end points.

TL;DR: The 2022 clinical practice guidelines, which are based on a literature review up to Jan 1, 2022, include guidance for patients with cancer and with COVID-19 and key recommendations include low-molecular-weight heparins for the initial treatment and maintenance treatment of cancer-associated thrombosis.